Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | GPR4 | P46093 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25771804 | 0.86 | USP30 (0.54) | USP30DGAT1GPR119PRMT5WDR77 | |
| SCHEMBL31212737 | 0.86 | USP30 (0.54) | USP30DGAT1GPR119PRMT5WDR77 | |
| SCHEMBL19459152 | 0.86 | EPHX2 (0.49) | USP30GPR119EPHX2GPR4AAK1 | |
| SCHEMBL17148720 | 0.83 | USP30 (0.55) | USP30DGAT1GPR119PRMT5WDR77 | |
| SCHEMBL30396496 | 0.83 | USP30 (0.55) | USP30DGAT1GPR119PRMT5WDR77 | |
| SCHEMBL4111762 | 0.81 | DGAT1 (0.49) | DGAT1 | |
| SCHEMBL20294780 | 0.81 | EPHX2 (0.48) | USP30EPHX2GPR4AAK1 | |
| SCHEMBL16990439 | 0.80 | USP30 (0.61) | USP30DGAT1GPR119 | |
| SCHEMBL17531642 | 0.80 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL182911 | 0.80 | USP30 (0.58) | USP30DGAT1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017516-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| EP-2970311-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | The Brigham and Women's Hospital, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | BMP1, BMPR2, BMP2 | USP30 2450/4885DGAT1 2378/4885CYP4F2 1490/4885 |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | BMP1, BMPR2, BMP2 | USP30 2450/4885DGAT1 2378/4885CYP4F2 1490/4885 |
| US-10017516-B2 | BMP inhibitors and methods of use thereof | BMP1, BMPR2, BMP2 | USP30 2450/4885DGAT1 2378/4885CYP4F2 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.